Thus, Feng et al. used EGFR-targeting CAR-T cells to treat patients with advanced and refractory non-small cell lung cancer with a strong positivity for EGFR expression (more than 50%), and the results indicate that 7 of the 11 enrolled patients were evaluable, including two with significant tumor reduction and five with stable disease [23]. Here, EGFR is linked to non-small cell lung carcinoma.